Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes

INTRODUCTION: The aim of the analysis was to characterize the population pharmacokinetics (PKs) and exposure–response (E–R) for efficacy (fasting plasma glucose, glycated hemoglobin) and safety/tolerability [hypoglycemia, genital infections, urinary tract infection (UTI), and volume depletion] of th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Diabetes Ther
Autores principales: Baron, Kyle T., Macha, Sreeraj, Broedl, Uli C., Nock, Valerie, Retlich, Silke, Riggs, Matthew
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5014782/
https://ncbi.nlm.nih.gov/pubmed/27312794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-016-0174-y
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares